Current Report Filing (8-k)
December 15 2021 - 4:31PM
Edgar (US Regulatory)
0000799698
false
0000799698
2021-12-09
2021-12-09
0000799698
CYTR:CommonStockParValue0.001PerShareMember
2021-12-09
2021-12-09
0000799698
CYTR:SeriesBJuniorParticipatingPreferredStockPurchaseRightsMember
2021-12-09
2021-12-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): December
9, 2021
CYTRX
CORPORATION
(Exact
name of registrant as specified in its charter)
Delaware
|
|
000-15327
|
|
58-1642740
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
11726
San Vicente Boulevard, Suite 650
Los
Angeles, California 90049
(Address
of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code: (310) 826-5648
None
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))
|
Securities
registered pursuant to Section 12(g) of the Act:
Title
of Each Class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common Stock, par value
$0.001 per share
|
|
CYTR
|
|
OTC Market
|
Series B Junior Participating
Preferred Stock Purchase Rights
|
|
|
|
OTC Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01 Other Events.
As
previously disclosed in definitive additional materials relating to our special meeting of stockholders (the “Special Meeting”)
that took place on September 23, 2021, on August 23, 2021, a stockholder of CytRx Corporation (the “Company”)
filed a class action lawsuit against the Company, Steven A. Kriegsman, Louis Ignarro, Joel K. Caldwell, and Jennifer K. Simpson claiming,
among other things, that the proxy statement in respect of the Special Meeting (the “Proxy Statement”) and
certain definitive additional materials were “materially incomplete” and that the individually named defendants “violated
the fiduciary duties they owe to the public stockholders of CytRx stock” (the “Class Action”). The plaintiff
sought, among other things, disclosure of certain information and an award of costs, disbursements, and certain professionals’
fees.
While the Company believed
strongly that the claims were without merit and that the information addressed in the lawsuit was not material or required under the
proxy rules, to avoid unnecessary distraction ahead of the Special Meeting, and without admitting any liability or wrongdoing, on September
9, 2021, the Company filed further definitive additional materials with the U.S. Securities and Exchange Commission amending and supplementing
the Proxy Statement (the “Proxy Supplement”). On September 10, 2021, the plaintiff determined to voluntarily
dismiss the Class Action in light of the supplemental disclosures in the Proxy Supplement, which dismissal was approved on September
13, 2021 by the Court of Chancery. The Court retained jurisdiction solely for the purpose of adjudicating
plaintiff’s counsel’s anticipated application for an award of attorneys’ fees and reimbursement of expenses.
The Company subsequently agreed to pay $110,000 to the plaintiff’s counsel in full satisfaction of his claim for attorneys’
fees and expenses in the Class Action. The Court of Chancery has not been asked to review, and will
pass no judgment on, the payment of a fee or its reasonableness.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
CYTRX CORPORATION
|
|
|
Date:December
15, 2021
|
/s/ John
Y. Caloz
|
|
John Y. Caloz
|
|
Chief Financial Officer
|
CytRx (QB) (USOTC:CYTR)
Historical Stock Chart
From Jul 2024 to Aug 2024
CytRx (QB) (USOTC:CYTR)
Historical Stock Chart
From Aug 2023 to Aug 2024